Abstract 498P
Background
Frailty is of importance for older lung cancer patients, but the remaining lifetime is still not estimated for frailty but solely relied on cancer stage or cell type. In this study, we aimed to estimate survival and life expectancy of older non-small cell lung cancer patients (NSCLC) by frailty status, using electronic-health records.
Methods
We retrospectively analyzed 4260 patients aged between 65 and 95 who were newly diagnosed with NSCLC in 2007-2018 in National Cancer Center, Korea and followed up until December 2020. Frailty was measured by laboratory tests before initial treatment (FI-Lab), then classified into non-frail (score <0.25) and frail groups (score>0.25). Kaplan-Meier curves and log-rank test were used to compare survival probabilities by frailty. Cox proportional hazard model were used to estimate effect of frailty on all-cause mortality, adjusted for age, sex and SEER stage. We also estimate average life expectancy by frailty for all patients and stratified by SEER stage.
Results
There were 1063 (25%) patients identified as being frail. Frail patients had a significantly poorer survival than the non-frail in total population, and in SEER stage groups. Overall, frailty is significantly associated with all-cause mortality (aHR: 1.65, 95% CI: 1.52-1.78). Average life expectancies of frail older patients were 7.75 (95% CI 6.48-9.27) years for localized stage, 3.55 (95% CI 3.05-4.08) years for regional stage and 0.89 (95% CI 0.78-1.02) years for distant stage. While these figures for non-frail patients diagnosed in same cancer stage were 10.05 (95% CI 9.49-11.38), 4.99 (95% CI 4.67-5.32), 1.94 (95%CI 1.82-2.06) respectively.
Conclusions
Survival and life expectancy of older NSCLC patients vary by frailty status. In clinical settings, frailty can be simply assessed by laboratory tests to provide more precise estimates of remaining life-year and help oncologists to better plan for treatment decision and follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Cancer Center Grant (No. NCC-2210880-2, NCC-2310450-1). In addition, one of the authors, Minh Thao Tu was supported by the “International Cooperation & Education Program” (NCCRI·NCCI 52210-52211, 2023)” of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract